DK1503746T3 - Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme - Google Patents

Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme

Info

Publication number
DK1503746T3
DK1503746T3 DK03731699T DK03731699T DK1503746T3 DK 1503746 T3 DK1503746 T3 DK 1503746T3 DK 03731699 T DK03731699 T DK 03731699T DK 03731699 T DK03731699 T DK 03731699T DK 1503746 T3 DK1503746 T3 DK 1503746T3
Authority
DK
Denmark
Prior art keywords
cox
angiogenesis
inhibitors
pharmaceutical use
eye diseases
Prior art date
Application number
DK03731699T
Other languages
English (en)
Inventor
Romulus Kimbro Brazzell
George N Lambrou
Elisabeth Latour
Anna Ottlecz
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1503746T3 publication Critical patent/DK1503746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK03731699T 2002-01-23 2003-01-22 Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme DK1503746T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201520.4A GB0201520D0 (en) 2002-01-23 2002-01-23 Pharmaceutical uses
PCT/EP2003/000612 WO2003061645A1 (en) 2002-01-23 2003-01-22 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders

Publications (1)

Publication Number Publication Date
DK1503746T3 true DK1503746T3 (da) 2008-02-04

Family

ID=9929598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03731699T DK1503746T3 (da) 2002-01-23 2003-01-22 Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme

Country Status (17)

Country Link
US (3) US20050043410A1 (da)
EP (1) EP1503746B1 (da)
JP (1) JP2005515241A (da)
CN (1) CN1283240C (da)
AR (1) AR038198A1 (da)
AT (1) ATE375154T1 (da)
BR (1) BR0307013A (da)
CA (1) CA2468811C (da)
CY (1) CY1106994T1 (da)
DE (1) DE60316792T2 (da)
DK (1) DK1503746T3 (da)
ES (1) ES2291641T3 (da)
GB (1) GB0201520D0 (da)
MY (1) MY145266A (da)
PT (1) PT1503746E (da)
TW (1) TWI280878B (da)
WO (1) WO2003061645A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
KR20110051245A (ko) * 2008-09-10 2011-05-17 제넨테크, 인크. 안구 혈관신생의 억제 방법
WO2010132634A1 (en) * 2009-05-15 2010-11-18 Glaxosmithkline Llc Using thermal imaging for control of a manufacturing process
WO2019070917A1 (en) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
KR100645866B1 (ko) * 1999-12-08 2006-11-15 파마시아 코포레이션 발데콕시브 조성물
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
BR0306777A (pt) * 2002-01-07 2005-04-26 Pharmacia Corp Tratamento de dor, inflamação e distúrbios relacionados à inflamação, com uma combinação de um inibidor seletivo de ciclooxigenase-2 e aspirina

Also Published As

Publication number Publication date
TW200302081A (en) 2003-08-01
ES2291641T3 (es) 2008-03-01
ATE375154T1 (de) 2007-10-15
CY1106994T1 (el) 2012-09-26
CA2468811C (en) 2011-08-09
EP1503746A1 (en) 2005-02-09
AR038198A1 (es) 2005-01-05
EP1503746B1 (en) 2007-10-10
TWI280878B (en) 2007-05-11
CA2468811A1 (en) 2003-07-31
DE60316792T2 (de) 2008-07-24
WO2003061645A1 (en) 2003-07-31
US20050043410A1 (en) 2005-02-24
CN1283240C (zh) 2006-11-08
JP2005515241A (ja) 2005-05-26
PT1503746E (pt) 2008-01-10
GB0201520D0 (en) 2002-03-13
US20120322874A1 (en) 2012-12-20
DE60316792D1 (de) 2007-11-22
MY145266A (en) 2012-01-13
BR0307013A (pt) 2004-11-03
CN1620288A (zh) 2005-05-25
US20090247638A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
MA29067B1 (fr) Protéines de fusion de RAGE et méthodes d'utilisation
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
IS7623A (is) Sískammtalausnar töflusamsetning úr pramipexóli
DK1620429T3 (da) Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
DK1542668T3 (da) Formulering af aripiprazolkompleks og fremgangsmåde
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DE60312780D1 (de) Wegwerfwindel
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1410793T3 (da) Administreringsform af ibuprofen-natrium
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
NO20050689L (no) Terapeutisk anvendelse
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1667693T3 (da) Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål
DK1503746T3 (da) Farmaceutisk anvendelse af COX-2-inhibitorer i angiogenesefremkaldte öjensygdomme
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DK1680405T3 (da) Bengamidderivater og deres anvendelse til behandling af kræftsygdomme
DK1515959T3 (da) Farmaceutiske salte af reboxetin
FR2844197B1 (fr) Solution pour application ungueale et peri-ungeale